Greenstone Biosciences and Intel Launch Strategic Collaboration to Scale AI-Enabled, Human-Centric Drug Discovery
核心洞察
Greenstone Biosciences (搜索) and Intel Corp. (搜索) announced a strategic collaboration to accelerate AI-enabled drug discovery using human iPSC biology and advanced computing infrastructure.
The partnership combines Greenstone's large-scale human biobank of induced pluripotent stem cells with Intel's Edge AI computing and purpose-built silicon for scaled data processing and analysis.
The collaboration aims to identify patient-specific response patterns, improve prediction of adverse drug effects, and advance precision medicine while reducing development costs.
Greenstone Biosciences (搜索), Inc. and Intel Corp. (搜索) (NASDAQ: INTC) have launched a strategic collaboration aimed at accelerating AI-enabled drug discovery by integrating Greenstone's large-scale human biobank of induced pluripotent stem cells (iPSCs) with Intel's Edge AI advanced computing and AI infrastructure. The partnership, announced on June 20, 2026, seeks to speed the development of new medicines by combining human genetics and biology with purpose-built silicon to scale data processing, storage, and analysis.
"This collaboration represents an important step toward more human-centered drug development," said Joseph C. Wu, M.D., Ph.D., Co-Founder of Greenstone Biosciences (搜索) and Director of the Stanford Cardiovascular Institute (SCVI). "By combining our iPSC-based systems with Intel's advanced computing architecture, we identify patient-specific response patterns, improve prediction of adverse drug effects, and advance new medicines more quickly and at a lower cost."
Leveraging the World's Largest Human iPSC Biobank
Greenstone Biosciences (搜索), a biotechnology company based in Stanford Research Park and co-founded by Dr. Wu, has built what it describes as the world's largest human biobank of induced pluripotent stem cells. The company specializes in New Approach Methodologies (NAMs), clinical genomics, iPSC platforms, artificial intelligence and machine learning, and drug development.
By pairing this extensive biological resource with Intel's computing capabilities, the collaboration is designed to enable population-scale analysis of human cellular models. The companies aim to generate insights that can identify how different patient populations may respond to drug candidates, potentially improving both the efficiency and safety profile of new therapeutics before they enter clinical trials.
Supporting Regulatory Momentum Toward NAMs
The collaboration aligns with growing regulatory interest in New Approach Methodologies. The companies noted that the initiative supports momentum around the FDA Modernization Act 3.0, as well as broader biotech and pharmaceutical industry efforts to complement traditional animal studies with human-relevant preclinical testing approaches.
By combining human cellular models, population-scale datasets, and AI-enabled analytics, Greenstone and Intel aim to help advance the next generation of drug safety assessment and medicine development. The approach is intended to improve the translational relevance of preclinical testing—a persistent challenge in pharmaceutical R&D where findings from animal models often fail to predict human outcomes.
The collaboration was highlighted during Intel's Computex 2026 keynote address, underscoring the strategic importance of applying advanced computing architectures to biomedical challenges. Recent publications, including work by Wu et al. (2026) in Science, Liu et al. (2026) in Cell, and Herron et al. (2025) in Nature, have further explored the implementation and opportunities for NAMs in drug discovery and development.